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Background-—The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) is a multicenter randomized trial of
stenting versus endarterectomy in patients with symptomatic and asymptomatic carotid disease. This study assesses management
of vascular risk factors.
Methods and Results-—Management was provided by the patient’s physician, with biannual monitoring results collected by the
local site. Therapeutic targets were low-density lipoprotein, cholesterol <100 mg/dL, systolic blood pressure <140 mm Hg,
fasting blood glucose <126 mg/dL, and nonsmoking status. Optimal control was defined as achieving all 4 goals concurrently.
Generalized estimating equations were used to compare risk factors at baseline with those observed in scheduled follow-up visits
for up to 48 months. In the analysis cohort of 2210, significant improvements in risk-factor control were observed across risk
factors for all follow-up visits compared with baseline. At 48 months, achievement of the low-density lipoprotein cholesterol goal
improved from 59.1% to 73.6% (P<0.001), achievement of the systolic blood pressure goal improved from 51.6% to 65.1%
(P<0.001), achievement of the glucose goal improved from 74.9% to 80.7% (P=0.0101), and nonsmoking improved from 74.4% to
80.9% (P<0.0001). The percentage with optimal risk-factor control also improved significantly, from 16.7% to 36.2% (P<0.001), but
nearly 2 of 3 study participants did not achieve optimal control during the study.
Conclusions-—Site-based risk-factor control improved significantly in the first 6 months and over the long term in CREST but was
often suboptimal. Intensive medical management should be considered for future trials of carotid revascularization.
Clinical Trial Registration-—URL: ClinicalTrials.gov. Unique identifier: NCT00004732. ( J Am Heart Assoc. 2014;3:e001180 doi:
10.1161/JAHA.114.001180)
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T reatment of hypertension, hyperlipidemia, and diabetesmellitus and assisting patients with cessation of ciga-
rette smoking are efficacious in preventing first-time1 and
recurrent2 stroke. The opportunities to favorably influence
blood pressure, cholesterol, and other vascular risk factors
are substantial. The prevalence in the United States of
persons with low risk-factor burden has been <11% for
decades.3 Intensive medical therapy has been associated with
a low absolute risk of stroke in patients with asymptomatic
carotid stenosis.4 Intensive statin therapy reduced the risk of
any stroke by 33% in the >1000 patients with known carotid
disease in the Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial.5 It is not known how well
vascular risk factors are controlled in this population at risk
for stroke. The Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREST) is a multicenter randomized
clinical trial of carotid stenting versus endarterectomy in
patients with symptomatic and asymptomatic carotid disease.
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ORIGINAL RESEARCH
The purpose of this study was to assess whether the methods
used in CREST to manage vascular risk factors resulted in
improvements in risk-factor status.
Methods
This study involves an exploratory analysis. The CREST trial
was approved by the local governing institutional review
board of each participating center, and all patients provided
written informed consent. The trial methods6 and primary
results7 have been published. The investigational devices,
the Acculink/RX Acculink carotid stent system and the
Accunet/RX Accunet, were manufactured by Abbott Vascu-
lar, Inc. The primary aim of the trial was to compare 2 types
of revascularization procedures, carotid endarterectomy and
carotid stenting; however, the investigators recognized that
monitoring and medical management of vascular risk factors
were essential for patient safety and overall stroke risk
reduction. Patients underwent twice-yearly assessments of
blood pressure, blood glucose, lipids, and cigarette smoking
status for the first 48 months of the trial. The medical
treatments were provided by the patient’s usual-care
physician. The principal investigators and study coordinators
at CREST participating centers were instructed to inform the
patients’ primary care physicians regarding the results of
the vascular-risk-factor assessments using a standardized
letter. Published American Heart Association guideline
statements for levels of control of blood pressure, glucose
in diabetic patients, and lipids were adopted studywide and
were provided to the usual-care physician. The importance
of appropriate concomitant medical therapy was empha-
sized at CREST investigators and annual coordinators
meetings throughout the course of the trial. Studywide
control of vascular risk factors was reported to and
monitored by the independent data and safety monitoring
board appointed by the National Institute of Neurological
Disorders and Stroke.
For this exploratory analysis, group means and rates for
risk factors were calculated using generalized estimating
equations (using an unstructured covariance matrix) to
account for the differences in sample sizes at each follow-
up visit while still accounting for the repeated measures for
Table 1. Vascular Risk Factors for Symptomatic and Asymptomatic Patients Enrolled in CREST*
Characteristic
Clinic Visit (Months)
0 (n=2210) 6 (n=1824) 12 (n=1742) 24 (n=1310) 36 (n=822) 48 (n=402)
LDL, mg/L
n 1961 1483 1495 1099 672 322
Mean (SE) 96.9 (0.8) 92.2 (0.8) 91 (0.8) 89.4 (0.9) 89.4 (1.1) 89.2 (1.4)
P value† <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Systolic BP, mm Hg
n 2180 1751 1656 1239 778 366
Mean (SE) 142.1 (0.4) 138 (0.5) 138.1 (0.5) 136.9 (0.5) 137.2 (0.7) 136.6 (0.9)
P value† <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Diastolic BP, mm Hg
n 2179 1747 1654 1239 779 367
Mean (SE) 73.9 (0.3) 75 (0.3) 74.3 (0.3) 73.6 (0.3) 73.7 (0.4) 72.6 (0.5)
P value† 0.0015 0.1884 0.4070 0.6593 0.0163
Glucose, mg/dL
n 2104 1544 1529 1112 667 318
Mean (SE) 116.9 (0.9) 114.8 (1.1) 114.4 (1.1) 114.3 (1.1) 116.3 (1.7) 115.4 (2.2)
P value† 0.0624 0.0264 0.0228 0.7095 0.5317
Current smoker
n 2169 1816 1740 1296 807 397
% 25.6 21.4 21.9 21.6 19.6 19.0
P value† <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
BP indicates blood pressure; CREST, Carotid Revascularization Endarterectomy vs Stenting Trial; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from a statistical model to account for missing data.
†P values test changes from baseline (note that changes from baseline on smoking are provided in Table 5).
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the same patient.8 This approach accounts for data missing
completely at random. Results were analyzed overall and
stratified by symptomatic status at baseline. In addition, rates
were calculated for achieving key benchmarks of blood
pressure, cholesterol, and glucose. To have a more sensitive
marker of successful risk factor control, an all-or-none
measurement was constructed post hoc.9 Patients were
considered to be optimally medically managed if they
achieved all of the following therapeutic goals: low-density
lipoprotein (LDL) cholesterol <100 mg/dL, glucose
<126 mg/dL, systolic blood pressure <140 mm Hg, and no
active cigarette smoking. To test for significant changes in
control of individual risk factors and achieving optimal
medical management, the generalized estimating equations
were used to calculate predicted percentages and to test for
significant differences from baseline. The analysis cohort
consisted of 2210 patients at enrollment; 1824 patients at 6
months; and 1742, 1320, 822, and 402 patients at 12, 24,
36, and 48-month follow-up, respectively. The glucose target
of <126 mg/dL was assessed for all patients regardless of
diabetic status.
Results
Patients were enrolled in CREST from December 21, 2000,
to July 18, 2008. Half of the patients were enrolled by
August 15, 2006. The last patient to be followed up to
48 months after randomization was seen January 20, 2010.
Table 1 shows that mean LDL cholesterol at baseline was
96.9 mg/dL. Median LDL cholesterol was 91.0 mg/dL
(interquartile range 46.0). Mean systolic blood pressure
was 142.1 mm Hg. Median systolic blood pressure was
140.0 mm Hg (interquartile range 27.0). Mean diastolic
blood pressure was 73.9 mm Hg. Median diastolic blood
pressure was 74.0 mm Hg (interquartile range 15.0). Mean
glucose concentration was 116.9 mg/dL. Median glucose
concentration was 104.0 mg/dL (interquartile range 33.0).
Approximately a quarter of the patients reported cigarette
smoking.
Table 1 also shows the status of vascular risk factors from
randomization to 48 months of follow-up for symptomatic and
asymptomatic patients overall. Tables 2 and 3 show the
status of these risk factors separately for symptomatic and
Table 2. Vascular Risk Factors for Patients Who Had Symptomatic Carotid Stenosis at Entry Into CREST*
Characteristic
Clinic Visit (Months)
0 6 12 24 36 48
LDL, mg/dL
n 947 689 680 524 363 225
Mean (SE) 102.3 (1.2) 96.1 (1.3) 94.5 (1.2) 92.7 (1.3) 91.7 (1.5) 92.3 (1.8)
P value† <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Systolic BP, mm Hg
n 1060 822 763 593 418 253
Mean (SE) 142.5 (0.6) 138.5 (0.7) 138.1 (0.7) 136.6 (0.8) 136.1 (0.9) 136.5 (1.1)
P value† <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Diastolic BP, mm Hg
n 1061 822 763 593 419 253
Mean (SE) 74.5 (0.4) 75.4 (0.4) 75 (0.4) 74.4 (0.4) 73.2 (0.5) 72.9 (0.6)
P value† 0.0589 0.3156 0.8368 0.0226 0.0212
Glucose, mg/dL
n 1029 719 703 538 362 221
Mean (SE) 114.4 (1.3) 113.2 (1.6) 114.9 (1.7) 115.1 (1.6) 117.6 (2.3) 115.9 (3)
P value† 0.4314 0.7903 0.6683 0.1704 0.6248
Current smoker
n 1053 866 821 632 442 284
% 27.3 21.9 22.8 22.2 21.1 21.0
P value† <0.0001 <0.0001 0.0001 <0.0001 <0.0001
BP indicates blood pressure; CREST, Carotid Revascularization Endarterectomy versus Stenting Trial; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from statistical model to account for missing data.
†P values test changes from baseline (note that changes from baseline on smoking are provided in Table 5).
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asymptomatic patients. In the period from December 21,
2000, to January 3, 2006, when the first third of patients were
enrolled in the trial, the rate of optimal risk-factor control at
enrollment was 14%. Table 4 shows the rates of optimal risk-
factor control at enrollment by calendar year of enrollment.
The proportion of patients achieving optimal control of the 4
risk-factor goals was 14.2% for the years 2000–2004 and
rose to >17% over the years 2005–2008, although the
improvements over time were not significant.
Table 5 shows the change in proportion of all patients
achieving targets for vascular risk factors from baseline to 6
months, from baseline to 12 months, from baseline to
24 months, from baseline to 36 months, and from baseline
to 48 months. The same outcomes are shown separately for
symptomatic and asymptomatic patients in Tables 6 and 7,
respectively. By 6 months, significant improvements were
observed for all therapeutic targets. The majority of patients
had achieved therapeutic targets for systolic blood pressure,
blood glucose, and cigarette smoking; however, less than two
thirds of patients achieved LDL cholesterol levels<100 mg/dL.
The rates for achieving a target LDL of <70 mg/dL were 22.9%
at baseline, 27.4% at 12 months (P=0.0003 versus baseline),
and 27.9% at 48 months (P=0.0258 versus baseline). Only
16.7% of patients had optimal risk-factor control at enrollment
Table 3. Vascular Risk Factors for Patients Who Had Asymptomatic Carotid Stenosis at Entry*
Characteristic
Clinic Visit (Months)
0 6 12 24 36 48
LDL, mg/dL
n 1014 794 815 575 309 97
Mean (SE) 91.9 (1.1) 88.5 (1.1) 87.8 (1.1) 86.4 (1.2) 87.3 (1.5) 84.1 (2.4)
P value† 0.0028 0.0005 <0.0001 0.0046 0.0020
Systolic BP, mm Hg
n 1120 929 893 646 360 113
Mean (SE) 141.8 (0.6) 137.5 (0.6) 138.2 (0.6) 137.1 (0.7) 138.3 (1) 136.8 (1.6)
P value† <0.0001 <0.0001 <0.0001 0.0010 0.0029
Diastolic BP, mm Hg
n 1118 925 891 646 360 114
Mean (SE) 73.3 (0.3) 74.6 (0.4) 73.8 (0.3) 72.9 (0.4) 74.4 (0.5) 72.2 (0.9)
P value† 0.0088 0.3270 0.3785 0.0822 0.2178
Glucose, mg/dL
n 1075 825 826 574 305 97
Mean (SE) 119.3 (1.3) 116.2 (1.6) 114.1 (1.3) 113.5 (1.6) 114 (2.3) 114.5 (2.7)
P value† 0.0605 0.0005 0.0005 0.0254 0.1033
Current smoker
n 1116 950 919 664 365 113
% 24.0% 21.1% 21.1% 21.0% 17.2% 14.5%
P value† 0.0037 0.0051 0.0102 <0.0001 0.0007
BP indicates blood pressure; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from statistical model to account for missing data.
†P values test changes from baseline (note that changes from baseline on smoking are provided in Table 5).
Table 4. Rates of Optimal Risk Factor Control at Enrollment











4 of 4 Goals† (%)
2000–2004 288 48.6 14.2
2005 348 53.7 14.1
2006 519 57.8 17.2
2007 478 60.7 19.3
2008 256 55.5 17.2
CREST indicates Carotid Revascularization Endarterectomy vs Stenting Trial; LDL, low-
density lipoprotein.
*Patients were considered to be optimally medically managed if they achieved at least 3
of the following therapeutic goals: LDL cholesterol <100 mg/dL, glucose <126 mg/dL,
systolic blood pressure <140 mm Hg, and no active cigarette smoking.
†Patients were considered to be optimally medically managed if they achieved all of the
following therapeutic goals: LDL cholesterol <100 mg/dL, glucose <126 mg/dL,
systolic blood pressure <140 mm Hg, and no active cigarette smoking.
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in the trial, and although the change at 6 months was
significant, this rate rose to only 27.1%. Significant benefits in
risk-factor control were observed across all risk factors
throughout follow-up. The percentage of patients achieving
the LDL cholesterol goal improved from 59.1% at baseline to
73.6% at 48 months (P<0.001). The percentage achieving the
systolic blood pressure goal improved from 51.6% to 65.1%
(P<0.001), and the percentage achieving the glucose goal
improved from 74.9% to 80.7% (P=0.0101). Nonsmoking
improved from 74.4% to 80.9% (P<0.0001). The percentage of
optimal risk-factor control improved from 16.7% at baseline to
36.2% at 48 months (P<0.001).
Discussion
We observed that the majority of participants had control of
blood pressure, glucose, and smoking but not LDL cholesterol
at the time of enrollment. Very early in the course of
participation in the trial, significant improvements were seen
for all 4 tracked risk factors. The improvements seen at
6 months of follow-up were sustained for up to 4 years. The
statistically significant improvement in risk factors, however,
should not obscure the fact that the absolute levels of control
of risk factors were far from ideal. Only 28% had achieved
optimal risk-factor control by 6 months, and only 35% had
achieved it by 48 months. These rates are comparable to the
rates of optimal risk-factor control achieved for patients
without diabetes and coronary artery disease enrolled in the
COURAGE trial and are substantially better than what was
achieved for patients with diabetes and coronary artery
disease in the COURAGE, BARI 2D, and FREEDOM trials.10
Our results may not reflect the epidemiology of risk-factor
control among patients with carotid stenosis. One would
anticipate that risk-factor control is poorer among the general
Table 5. Changes in Goals Attained From Baseline to 6, 12, 24, 36, and 48 Months for Symptomatic and Asymptomatic Patients
Characteristic
Clinic Visit (Months)
0 (n=2210) 6 (n=1824) 12 (n=1742) 24 (n=1310) 36 (n=822) 48 (n=402)
LDL cholesterol <100 mg/dL
n 1160 998 1033 769 469 235
Achieved goal %* 59.1 67.0 68.4 69.1 69.8 73.6
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Systolic BP <140 mm Hg
n 1124 1079 1003 792 492 237
Achieved goal %* 51.6 61.7 60.7 64.1 64.1 65.1
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Glucose at target
n 1573 1270 1253 919 559 255
Achieved goal %* 74.9 82.0 81.9 81.8 82.4 80.7
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 0.0101
Nonsmoker
n 1611 1435 1367 1049 673 328
Achieved goal %* 74.4 78.6 78.1 78.4 80.4 80.9
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Rate of achieving at least 3 of 4 goals
n 1059 974 983 753 440 218
Achieved goal %* 56.2 69.2 69.4 71.9 71.7 74.6
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Rate of achieving 4 of 4 goals
n 315 384 381 305 196 104
Achieved goal %* 16.7 27.1 26.8 29.0 32.0 36.2
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
BP indicates blood pressure; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from statistical model to account for missing data.
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population with carotid stenosis because of the healthy-
participant bias. Consequently, there may be an even greater
opportunity to improve vascular risk factors in the general
population of patients with carotid atherosclerosis. For
patients with coronary artery disease, there is considerable
opportunity to improve vascular risk factors. Among the
>3000 patients with self-reported coronary artery disease in
the REGARDS study, only 16% met all 3 goals for aspirin,
blood pressure, and LDL cholesterol.11
CREST had no treatment group that received only medical
therapy. Emphasis in the trial was placed on selecting sites
with outstanding surgical and interventional teams and
ensuring low risk for periprocedure stroke following either
carotid endarterectomy or carotid stenting. The medical
management was decentralized, even beyond the site level,
because it was often provided by the usual-care physician
(generally the referring physician). Accordingly, aggressive
and timely control of risk factors by the site or by the CREST
central leadership was not feasible. The results of the medical
monitoring were provided to the usual-care physician, but
whether or not the results were acted on when provided (eg,
systolic blood pressures ≥140 mm Hg or LDLs ≥100 mg/dL)
or how they were acted on could not be determined.
The enrollment period for CREST was 7.5 years from 2000
until midyear 2008. During this time, risk-factor-management
guidelines for primary and secondary prevention of stroke
were published and widely disseminated.1,2 Consequently, it
is not surprising that control of risk factors at baseline
improved in comparisons of the earlier years of enrollment to
the later years. In the secondary prevention trial, Vitamin
Intervention for Stroke Prevention (VISP), control of several
risk factors at baseline also improved significantly during the
4.4-year recruitment period from August 1997 to December
2001.12 Hypertension and hypercholesterolemia management
Table 6. Changes in Goals Attained From Baseline to 6, 12, 24, 36 and 48 Months for Symptomatic Patients
Characteristic
Clinic Visit (Months)
0 6 12 24 36 48
LDL cholesterol <100 mg/dL
n 494 422 435 347 244 153
Achieved goal %* 52.0 60.5 63.4 65.0 66.8 68.9
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Systolic BP <140 mm Hg
n 534 496 463 385 271 162
Achieved goal %* 50.4 60.4 61.1 64.8 65.5 64.1
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Glucose at target
n 811 603 593 453 299 179
Achieved goal %* 79.0 83.8 84.3 83.0 80.9 81.7
P value for difference from baseline 0.0008 0.0002 0.0157 0.3176 0.3100
Nonsmoker
n 764 677 637 507 363 233
Achieved goal %* 72.7 78.1 77.2 77.8 78.8 78.9
P value for difference from baseline <0.0001 <0.0001 0.0001 <0.0001 <0.0001
Rate of achieving at least 3 of 4 goals
n 479 424 428 365 233 144
Achieved goal %* 52.8 65.4 67.8 72.0 69.8 71.9
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Rate of achieving 4 of 4 goals
n 138 160 170 142 99 73
Achieved goal %* 15.2 25.1 26.8 27.1 29.4 35.4
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
BP indicates blood pressure; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from statistical model to account for missing data.
DOI: 10.1161/JAHA.114.001180 Journal of the American Heart Association 6















and control improved; there was an increase in use of
antiplatelet medications, newer classes of antihypertensive
medications, and lipid-lowering drugs.12 Similar to the CREST
recruitment period, during the VISP enrollment period,
national guidelines were released in addition to results from
other secondary prevention trials. For stroke prevention trials
with long recruitment periods, it is important that risk-factor
management be standardized and be as stable as possible
across all treatment groups so as not to differentially reduce
the event rate and thus the ability of the trial to detect
treatment effects.13
There is growing interest in conducting a randomized trial
to compare intensive medical therapy and revascularization,
similar to what has been done for stable coronary disease,14
atherosclerotic renal artery stenosis,15 and intracranial cere-
brovascular disease.16 In the Stenting Versus Aggressive
Medical Management for Intracranial Stenosis (SAMMPRIS)
study, a centralized model for treatment of risk factors was
used. Management of medications for risk factors was
provided by the local-site neurologist but was specified in a
step-by-step protocol. Adherence to the protocol was mon-
itored and enforced centrally by a SAMMPRIS medical core;
lifestyle coaching was also provided by a national provider
under direction of the SAMMPRIS medical core. The control of
risk factors was exceptional with these methods. At baseline,
4 months, and 1 year, the mean systolic blood pressure was
146.821.8, 134.817.0, and 133.817.1 mm Hg, respec-
tively. For LDL, the results at baseline, 4 months, and 1 year
were 97.736.6, 72.826.0, and 68.227.5 mg/dL, respec-
tively. Consequently, along with the results we report in this
paper, SAMMPRIS suggests that achieving intensive thera-
peutic targets with medical therapy may require a tightly
integrated organizational model with close central manage-
ment of a hands-on local medical management team. The
Table 7. Changes in Goals Attained From Baseline to 6, 12, 24, 36 and 48 Months for Asymptomatic Patients
Characteristic
Clinic Visit (Months)
0 6 12 24 36 48
LDL cholesterol <100 mg/dL
n 666 576 598 422 225 82
Achieved goal %* 65.7 73.0 73.1 72.7 72.1 82.3
P value for difference from baseline <0.0001 <0.0001 0.0006 0.0122 0.0002
Systolic BP <140 mm Hg
n 590 583 540 407 221 75
Achieved goal %* 52.7 63.0 60.4 63.7 62.8 67.2
P value for difference from baseline <0.0001 0.0002 <0.0001 0.0004 0.0024
Glucose at target
n 762 667 660 466 260 76
Achieved goal %* 71.0 80.3 79.7 80.7 84.7 82.0
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 0.0118
Nonsmoker
n 847 758 730 542 310 95
Achieved goal %* 76.0 79.0 79.0 79.0 82.8 85.5
P value for difference from baseline 0.0030 0.0050 0.0098 <0.0001 0.0007
Rate of achieving at least 3 of 4 goals
n 580 550 555 388 207 74
Achieved goal %* 59.4 72.6 70.9 71.9 73.4 82.0
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Rate of achieving 4 of 4 goals
n 177 224 211 163 97 31
Achieved goal %* 18.2 29.0 27.0 30.4 34.5 36.0
P value for difference from baseline <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
BP indicates blood pressure; LDL, low-density lipoprotein.
*Values (and SE) are the predicted values from statistical model to account for missing data.
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soon-to-be-initiated CREST-2 trial of intensive medical man-
agement with or without revascularization in patients with
asymptomatic carotid stenosis will use such an approach to
management of vascular risk factors.17
The so-called inclusion benefit has not been clearly
demonstrated in cancer trials18; however, it may be present
in trials like CREST-2, in which proven therapies will be given
to all patients adjunctive to the interventions to which the
patients are being randomized. We do not know how risk
factors changed for patients who were eligible for CREST but
who refused participation. Nonetheless, we suspect that
patients benefited from being included in the trial because
favorable effects were observed across key vascular risk
factors. In CREST, adherence to evidence-based guidelines
was promoted across clinical centers. Such guidelines have
been shown to improve clinical practice.19 It is both surprising
and disappointing that the rates of optimal risk-factor control,
although relatively improved, remain poor in an absolute
sense. One might have anticipated a greater effect on
behaviors of the treating physicians; however, reasons for
lack of risk-factor control are multifaceted and involve not
only the treating physicians but also other healthcare
providers, the healthcare system, and the individual patient.
Related reasons include medication noncompliance, inade-
quate therapy, and inappropriate therapy.
A limitation of our study is that data are provided on only 4
metrics for vascular risk factors. Data were not available for
other important risk factors such as frequency of exercise or
quality of diet. In addition, not every patient enrolled in the
study had every follow-up visit, and not every risk factor was
assessed at every follow-up visit. Loss to follow-up was more
problematic for the later visits than for the earlier visits.
Although missing visits did not occur at random, the
proportion of missed visits was very low and was unlikely to
have altered the basic conclusions that risk factors improved
and that optimal risk-factor control was rarely achieved.
Cigarette smoking was assessed by self-report and not by
objective measures such as the detection of nicotine
metabolites in serum; however, smoking status tends to be
slightly underestimated by self-report.20 This implies that the
rate of 17% for active smoking at 48 months after random-
ization conservatively estimates the true active smoking rate.
Conclusion
In conclusion, significant improvements were seen in control
of vascular risk factors in patients enrolled in CREST.
However, substantial opportunities remained for most
patients to further improve upon medical management.
Future carotid interventional trials should place increasing
emphasis on controlling vascular risk factors.
Sources of Funding
CREST was funded by the National Institute of Neurological
Disorders and Stroke (US) (R01 NS038384) with additional




1. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager
MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR,
Meschia JF, Moore WS, Nixon JV, Pearson TA. Guidelines for the primary
prevention of stroke: a guideline for healthcare professionals from the American
Heart Association/American Stroke Association. Stroke. 2011;42:517–584.
2. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL,
Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY,
Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D.
Guidelines for the prevention of stroke in patients with stroke or transient
ischemic attack: a guideline for healthcare professionals from the American
Heart Association/American Stroke Association. Stroke. 2011;42:227–276.
3. Ford ES, Li C, Zhao G, Pearson WS, Capewell S. Trends in the prevalence of low
risk factor burden for cardiovascular disease among United States adults.
Circulation. 2009;120:1181–1188.
4. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke
in patients with asymptomatic carotid stenosis on best medical treatment: a
prospective, population-based study. Stroke. 2010;41:e11–e17.
5. Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J,
Messig M, Welch KM. Atorvastatin reduces the risk of cardiovascular events in
patients with carotid atherosclerosis: a secondary analysis of the Stroke
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Stroke. 2008;39:3297–3302.
6. Sheffet AJ, Roubin G, Howard G, Howard V, Moore W, Meschia J, Hobson RW II,
Brott TG. Design of the Carotid Revascularization Endarterectomy vs. Stenting
Trial (CREST). Int J Stroke. 2010;5:40–46.
7. Brott TG, Hobson RW II, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A,
Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins
LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL,
Silver FL, Mohr JP, Lal BK, Meschia JF; Investigators C. Stenting versus
endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;
363:11–23.
8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models.
Biometrika. 1986;73:13–22.
9. Nolan T, Berwick DM. All-or-none measurement raises the bar on performance.
JAMA. 2006;295:1168–1170.
10. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M,
Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V.
Risk factor control for coronary artery disease secondary prevention in large
randomized trials. J Am Coll Cardiol. 2013;61:1607–1615.
11. Brown TM, Voeks JH, Bittner V, Brenner DA, Cushman M, Goff DC Jr, Glasser S,
Muntner P, Tabereaux PB, Safford MM. Achievement of optimal medical
therapy goals for U.S. Adults with coronary artery disease: results from the
REGARDS Study (reasons for geographic and racial differences in stroke). J Am
Coll Cardiol. 2014;63:1626–1633.
12. Howard VJ, Furie KL, Wang CH, Sides EG, Toole JF. The changing risk factor
profile of participants enrolled in a secondary stroke prevention trial: vitamin
intervention for stroke prevention. Neuroepidemiology. 2006;27:222–229.
13. Hong KS, Yegiaian S, Lee M, Lee J, Saver JL. Declining stroke and vascular
event recurrence rates in secondary prevention trials over the past 50 years
and consequences for current trial design. Circulation. 2011;123:2111–2119.
14. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson
M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz
S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS,
Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for
stable coronary disease. N Engl J Med. 2007;356:1503–1516.
15. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ,
Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI,
Rundback JH, Massaro JM, D’Agostino RB Sr, Dworkin LD. Stenting and medical
therapy for atherosclerotic renal-artery stenosis.NEngl JMed. 2014;370:13–22.
DOI: 10.1161/JAHA.114.001180 Journal of the American Heart Association 8















16. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS,
Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh
BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP,
Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Lynch JR, Zaidat OO,
Rumboldt Z, Cloft HJ. Aggressive medical treatment with or without stenting in
high-risk patients with intracranial artery stenosis (SAMMPRIS): the final
results of a randomised trial. Lancet. 2014;383:333–341.
17. Rubin MN, Barrett KM, Brott TG, Meschia JF. Asymptomatic carotid stenosis:
what we can learn from the next generation of randomized clinical trials. JRSM
Cardiovasc Dis. 2014;3:2048004014529419.
18. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer
patients treated within and outside clinical trials: conceptual framework and
structured review. Lancet. 2004;363:263–270.
19. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a
systematic review of rigorous evaluations. Lancet. 1993;342:1317–1322.
20. Connor Gorber S, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The
accuracy of self-reported smoking: a systematic review of the relationship
between self-reported and cotinine-assessed smoking status. Nicotine Tob
Res. 2009;11:12–24.
DOI: 10.1161/JAHA.114.001180 Journal of the American Heart Association 9
Risk Factors in CREST Meschia et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
